Using technology to address issues of diversity and inclusion across the drug development lifecycle.
Improving diversity and inclusion in life science is more than just the right thing to do – there’s also a sound business imperative to do so.
Diversity in clinical trial recruitment is a significant shortfall for life science companies, with a number of barriers to participation excluding underserved communities.
“53% of non-Hispanic white participants said that they trusted their health professionals ‘a lot,’ compared with 37% for non-Hispanic black participants and 36% for Hispanic participants.”
Technologies including artificial intelligence, network analytics, social listening, and virtual asynchronous engagement are helping to remove these barriers to trial participation.
An AI-enhanced trial at Cedars-Sinai identified 16 candidates in one hour, while a human-based approach found two people in six months.
Social media is already being used for patient recruitment on 11% of clinical trials globally, where this activity is underpinned by some level of online media monitoring. – PREVENTCANCER.ORG
Expert identification is another area where life science falls short, with many companies continuing to rely on the same pool of established KOLs.
Network analytics can reveal the ‘invisible college’ within a disease community, based on true network influence rather than volume of activity.
Even when diversity has been achieved, hierarchy bias within the life science sector prevents all voices from being heard.
of female business leaders say it’s difficult for women to speak up in virtual meetings. – CATALYST